| Adenosine receptors as a biological pathway for the anti-inflammatory and beneficial effects of low frequency low energy pulsed electromagnetic fields K Varani, F Vincenzi, A Ravani, S Pasquini, S Merighi, S Gessi, S Setti, ... Mediators of inflammation 2017, 2017 | 95 | 2017 |
| Adenosine and inflammation: here, there and everywhere S Pasquini, C Contri, PA Borea, F Vincenzi, K Varani International journal of molecular sciences 22 (14), 7685, 2021 | 83 | 2021 |
| Pulsed electromagnetic field exposure reduces hypoxia and inflammation damage in neuron‐like and microglial cells F Vincenzi, A Ravani, S Pasquini, S Merighi, S Gessi, S Setti, R Cadossi, ... Journal of Cellular Physiology 232 (5), 1200-1208, 2017 | 79 | 2017 |
| Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis A Ravani, F Vincenzi, A Bortoluzzi, M Padovan, S Pasquini, S Gessi, ... International Journal of Molecular Sciences 18 (4), 697, 2017 | 59 | 2017 |
| Pulsed electromagnetic field stimulation in osteogenesis and chondrogenesis: signaling pathways and therapeutic implications K Varani, F Vincenzi, S Pasquini, I Blo, S Salati, M Cadossi, M De Mattei International Journal of Molecular Sciences 22 (2), 809, 2021 | 57 | 2021 |
| Targeting adenosine receptors: a potential pharmacological avenue for acute and chronic pain F Vincenzi, S Pasquini, PA Borea, K Varani International Journal of Molecular Sciences 21 (22), 8710, 2020 | 52 | 2020 |
| Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety F Vincenzi, A Ravani, S Pasquini, S Merighi, S Gessi, R Romagnoli, ... Neuropharmacology 111, 283-292, 2016 | 36 | 2016 |
| Adenosine receptors in neuropsychiatric disorders: fine regulators of neurotransmission and potential therapeutic targets S Pasquini, C Contri, S Merighi, S Gessi, PA Borea, K Varani, F Vincenzi International Journal of Molecular Sciences 23 (3), 1219, 2022 | 27 | 2022 |
| Polypharmacological approaches for CNS diseases: focus on endocannabinoid degradation inhibition A Papa, S Pasquini, C Contri, S Gemma, G Campiani, S Butini, K Varani, ... Cells 11 (3), 471, 2022 | 25 | 2022 |
| Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer’s Disease S Merighi, PA Borea, K Varani, F Vincenzi, A Travagli, M Nigro, ... Molecules 27 (9), 2680, 2022 | 18 | 2022 |
| Modifications on the amino-3, 5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity M Betti, D Catarzi, F Varano, M Falsini, K Varani, F Vincenzi, S Pasquini, ... Journal of Medicinal Chemistry 62 (15), 6894-6912, 2019 | 18 | 2019 |
| Identification of novel thiazolo [5, 4-d] pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists F Varano, D Catarzi, M Falsini, F Vincenzi, S Pasquini, K Varani, V Colotta Bioorganic & Medicinal Chemistry 26 (12), 3688-3695, 2018 | 17 | 2018 |
| A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease S Gessi, TE Poloni, G Negro, K Varani, S Pasquini, F Vincenzi, PA Borea, ... Cells 10 (9), 2344, 2021 | 16 | 2021 |
| The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and … L Squarcialupi, M Betti, D Catarzi, F Varano, M Falsini, A Ravani, ... Journal of Enzyme Inhibition and Medicinal Chemistry 32 (1), 248-263, 2017 | 16 | 2017 |
| A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma F Vincenzi, JC Rotondo, S Pasquini, F Di Virgilio, K Varani, M Tognon Frontiers in Oncology 11, 679285, 2021 | 15 | 2021 |
| An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment? S Merighi, TE Poloni, L Pelloni, S Pasquini, K Varani, F Vincenzi, ... Frontiers in Pharmacology 12, 652455, 2021 | 15 | 2021 |
| A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity? S Merighi, M Nigro, A Travagli, S Pasquini, PA Borea, K Varani, ... International journal of molecular sciences 23 (9), 5056, 2022 | 14 | 2022 |
| The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A1AR Positive … F Vincenzi, S Pasquini, S Gessi, S Merighi, R Romagnoli, PA Borea, ... Cells 9 (5), 1242, 2020 | 13 | 2020 |
| Structural investigation on thiazolo [5, 4-d] pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents F Varano, D Catarzi, F Vincenzi, S Pasquini, J Pelletier, JLR Fietto, ... Bioorganic & Medicinal Chemistry Letters 30 (9), 127067, 2020 | 13 | 2020 |
| Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl) thiazolo [5, 4-d] pyrimidine-5, 7-diamine-based … F Varano, D Catarzi, F Vincenzi, M Falsini, S Pasquini, PA Borea, ... European Journal of Medicinal Chemistry 155, 552-561, 2018 | 13 | 2018 |
